论文部分内容阅读
后程加速放疗用以提高食管癌局控率，评价新辅助化疗地位。选择40例不宜手术治疗的食管癌患者应用本法治疗。后程加速采用同时小野加量技术，使平均剂量达68．4Gy，在46d内完成。其中70％患者接受新辅助化疗。结果：T1、T2、T3期患者3a累计局控率分别为73％、48％、36％，3a无局部复发累计生存率分别为41％、24％、9％。多因素分析提示，T分期及总治疗时间为生存率独立预后因子，而新辅助化疗非预后因子。结论：后程加速放疗对较早期食管癌有价值，而新辅助化疗未显示出优势。
Accelerated radiotherapy is used to increase the rate of esophageal cancer control and evaluate the status of neoadjuvant chemotherapy. 40 patients with esophageal cancer who were not suitable for surgical treatment were treated with this method. Accelerate the use of late-course acceleration using the same technology, so that the average dose of 68.4Gy, completed in 46d. Of these, 70% received neoadjuvant chemotherapy. Results: The cumulative local control rate in patients with T1, T2, and T3 at 3 years was 73%, 48%, and 36%, respectively. The cumulative survival rate of 3a without local recurrence was 41%, 24%, and 9%, respectively. Multivariate analysis suggested that T staging and total treatment time were independent prognostic factors for survival, while neoadjuvant chemotherapy was not a prognostic factor. Conclusions: Late course accelerated radiotherapy is valuable for early esophageal cancer, and neoadjuvant chemotherapy does not show an advantage.